Article
Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study.
Cancer communications (London, England) - 1 Jan 2026
Yang Sheng, Zhao Yanqiu, Sun Meili, Bi Minghong, Zhu Bo, Chen Zhaohong, Yu Huiqing, Zhang Liangming, Wu Lin, Zhou Rui, Yao Wenxiu, Li Xingya, Han Zhigang, Wang Ke, Wang Lijun, Wen Meiling, Guo Yanzhen, Lin Yingcheng, Sun Shenghua, Guo Shuliang, Yi Tienan, Zhao Wenhua, Yu Zhuang, Qin Jianwen, Pan Yueyin, He Zhiyong, Ye Feng, Shi Huaqiu, Fang Jian, Ma Rui, Lu Hong, Zhang Hua, Shi Jianhua, Gao Jinghua, Cui Jiuwei, Li Manxiang, Yi Shanyong, Cang Shundong, Shu Yongqian, Zhang Don, Peng Jirong, Gao Feng, Wang Tingting, Zhou Anqi, Shi Yuankai
Abstract excerpt
Background: From 2019 July 15 to 2022 February 14, the REZOR study enrolled 369 treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations (exon 19 deletion or L858R mutation). Patients were randomly assigned 1:1 to receive either rezivertinib (180 mg/d) plus gefitinib placebo or gefitinib (250 mg/d) plus rezivertinib placebo. Previous results demonstrated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.